|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,175.55 INR | -0.92% |
|
-2.80% | -7.51% |
| Capitalization | 988B 10.93B 9.42B 8.78B 8.16B 15.19B 16.29B 101B 39.68B 472B 40.99B 40.16B 1,732B | P/E ratio 2026 * |
19x | P/E ratio 2027 * | 21.4x |
|---|---|---|---|---|---|
| Enterprise value | 956B 10.58B 9.11B 8.49B 7.9B 14.7B 15.77B 97.58B 38.4B 457B 39.67B 38.86B 1,676B | EV / Sales 2026 * |
2.79x | EV / Sales 2027 * | 2.65x |
| Free-Float |
70.34% | Yield 2026 * |
0.76% | Yield 2027 * | 0.75% |
Last Transcript: Dr. Reddy's Laboratories Limited
| 1 day | -0.92% | ||
| 1 week | -2.80% | ||
| Current month | -7.51% | ||
| 1 month | -8.09% | ||
| 3 months | -5.20% | ||
| 6 months | -6.62% | ||
| Current year | -7.51% |
| 1 week | 1,172 |  | 1,218.8 |
| 1 month | 1,172 | | 1,291 |
| Current year | 1,172 | | 1,265.15 |
| 1 year | 1,025.9 | | 1,377.95 |
| 3 years | 835.37 | | 1,420.2 |
| 5 years | 731 | | 1,420.2 |
| 10 years | 377.6 | | 1,420.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 59 | 30/06/2019 |
B. Phanimitra
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/2023 |
K. Randhir Singh
CMP | Compliance Officer | - | 16/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 58 | 12/05/2014 | |
Gunupati Prasad
CHM | Chairman | 65 | 01/04/2013 |
Leo Puri
BRD | Director/Board Member | 65 | 24/10/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.92% | -2.80% | -9.80% | +35.85% | 10.93B | |
| -3.76% | -4.81% | +38.33% | +185.65% | 925B | |
| +0.47% | +6.72% | +51.46% | +26.60% | 529B | |
| -2.32% | -3.29% | +26.50% | +41.11% | 383B | |
| +0.95% | +2.32% | +29.82% | +18.36% | 368B | |
| +0.70% | -0.68% | +30.21% | +20.93% | 291B | |
| +1.07% | +1.46% | +27.72% | +34.19% | 274B | |
| -0.04% | -0.02% | +10.87% | -1.14% | 275B | |
| +4.34% | +0.26% | -36.44% | -19.71% | 252B | |
| +0.32% | -0.02% | +22.72% | +21.46% | 178B | |
| Average | +0.35% | -0.59% | +19.14% | +36.33% | 348.57B | |
| Weighted average by Cap. | +0.30% | -0.58% | +28.09% | +63.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 342B 3.79B 3.26B 3.04B 2.83B 5.26B 5.64B 34.93B 13.74B 164B 14.2B 13.91B 600B | 349B 3.87B 3.33B 3.11B 2.89B 5.37B 5.76B 35.68B 14.04B 167B 14.5B 14.21B 613B |
| Net income | 51.74B 573M 493M 460M 428M 796M 853M 5.28B 2.08B 24.73B 2.15B 2.1B 90.73B | 46.52B 515M 443M 413M 384M 715M 767M 4.75B 1.87B 22.24B 1.93B 1.89B 81.58B |
| Net Debt | -31.85B -352M -304M -283M -263M -490M -525M -3.25B -1.28B -15.23B -1.32B -1.29B -55.86B | -61.45B -680M -586M -546M -508M -945M -1.01B -6.27B -2.47B -29.38B -2.55B -2.5B -108B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 1,175.55 ₹ | -0.92% | 608,516 |
| 14/01/26 | 1,186.45 ₹ | -0.33% | 37,978 |
| 13/01/26 | 1,190.35 ₹ | -2.08% | 63,452 |
| 12/01/26 | 1,215.65 ₹ | +0.51% | 29,015 |
| 09/01/26 | 1,209.45 ₹ | +0.16% | 135,073 |
Delayed Quote Bombay S.E., January 16, 2026 at 10:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DRREDDY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition